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ABSTRACT
Introduction COVID-19 vaccines are now being 
distributed to low- and middle- income countries (LMICs), 
with global urgency surrounding national vaccination 
plans. LMICs have significant experience implementing 
vaccination campaigns to respond to epidemic threats but 
are often hindered by chronic health system challenges. 
We sought to identify transferable lessons for COVID-19 
vaccination from the rollout of three vaccines that targeted 
adult groups in Africa and South America: MenAfriVac 
(meningitis A); 17D (yellow fever) and rVSV- ZEBOV (Ebola 
virus disease).
Methods We conducted a rapid literature review and 24 
semi- structured interviews with technical experts who had 
direct implementation experience with the selected vaccines 
in Africa and South America. We identified barriers, enablers, 
and key lessons from the literature and from participants’ 
experiences. Interview data were analysed thematically 
according to seven implementation domains.
Results Participants highlighted multiple components 
of vaccination campaigns that are instrumental for 
achieving high coverage. Community engagement is an 
essential and effective tool, requiring dedicated time, 
funding and workforce. Involving local health workers is 
a key enabler, as is collaborating with community leaders 
to map social groups and tailor vaccination strategies to 
their needs. Vaccination team recruitment and training 
strategies need to be enhanced to support vaccination 
campaigns. Although recognised as challenging, 
integrating vaccination campaigns with other routine 
health services can be highly beneficial if well planned 
and coordinated across health programmes and with 
communities.
Conclusion As supplies of COVID-19 vaccines become 
available to LMICs, countries need to prepare to efficiently 
roll out the vaccine, encourage uptake among eligible 
groups and respond to potential community concerns. 
Lessons from the implementation of these three vaccines 
that targeted adults in LMICs can be used to inform best 
practice for COVID-19 and other epidemic vaccination 
campaigns.
Key questions
What is already known?
 ► Low- and middle- income countries (LMICs) have 
substantial experience conducting vaccination 
campaigns as a part of epidemic responses.
 ► Vaccination campaigns in LMICs are impacted 
by a number of systemic challenges, including 
poor infrastructure, limited resources and an 
overstretched health workforce.
 ► Meningitis A, yellow fever and Ebola virus disease 
vaccines have been recently rolled out in LMICs 
to respond to epidemic threats; these campaigns 
share some of the same challenges anticipated for 
COVID-19 vaccination, including the focus on adult 
target groups.
What are the new findings?
 ► Extensive community engagement is crucial 
when targeting adults for vaccination in LMICs to 
shift community perceptions that vaccination is 
only associated with children.
 ► Working with community leaders to map social 
groups and plan effective vaccination strat-
egies is vital to achieving high vaccination 
coverage.
 ► Recruiting local health workers who have es-
tablished links to the community, can speak the 
local language and can leverage existing rapport 
to increase vaccination uptake is preferred over 
bringing in staff from other regions.
 ► Vaccination training quality is reduced as infor-
mation is transmitted down to lower levels using 
the ‘cascade’ or ‘training- of- trainers’ model.
 ► Training for vaccination campaigns in LMICs has 
been further affected by COVID-19 and the move 
to remote learning.
 ► Where access to training is limited, a greater 
emphasis is placed on resource- intensive super-
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INTRODUCTION
Development and mass production of multiple safe and 
effective COVID-19 vaccines have progressed faster than 
expected. There are signs that, with high population- level 
vaccination coverage, pre- pandemic levels of mobility 
and economic activity could safely resume.1 2 However, 
COVID-19 vaccination has been dominated by high- 
income countries, which have purchased 51% of vaccine 
doses yet represent only 14% of the global population.3 
As of 10 July 2021, only 1% of people in low- income 
countries had received at least one dose of a COVID-19 
vaccine.4 Adequate vaccine supply is a critical first step. 
Access mechanisms, such as the COVID-19 Vaccines 
Global Access (COVAX) initiative, have been established 
to support vaccine supply in low- and middle- income 
countries (LMICs); however, modest initial targets have 
not been met.5 In addition to increasing access to vaccine 
supplies, critical work is needed to ensure that vaccines 
reach their intended target groups.
Many factors can complicate vaccine rollouts in LMICs, 
including limited health and surveillance infrastruc-
ture, insufficient cold chain transportation and storage 
capacity, and an under- resourced health workforce.6 7 
Previous research has focused on the barriers to achieving 
high vaccination coverage in LMICs during routine 
vaccination campaigns, primarily targeting children.8–10 
This study aims to identify barriers, enablers and lessons 
from vaccination campaigns conducted to prevent or 
respond to epidemics, with a focus on adult target popu-
lations. Some LMICs have substantial experience in 
conducting vaccination campaigns to prevent or respond 
to epidemics, from which valuable lessons can be drawn 
for the rollout of COVID-19 vaccines.
We examined vaccination campaigns recently 
conducted as part of epidemic responses (hereafter, 
‘vaccination campaigns’) in LMICs in Africa and South 
America. We selected three vaccines—MenAfriVac 
(meningitis A), 17D (yellow fever) and rVSV- ZEBOV 
(Ebola virus disease (EVD))—that share some of the same 
challenges anticipated for COVID-19 in LMICs (table 1) 
to capture insights and make recommendations for coun-
tries implementing COVID-19 vaccination campaigns.
METHODS
We conducted a rapid literature review followed by semi- 
structured interviews with technical experts to identify 
barriers, enablers, and lessons from implementing the 
three vaccines in recent outbreaks in Africa and South 
America.
We designed a thematic framework of seven domains 
(table 2) to guide the research, based on existing vaccine 
readiness assessment tools and gap analyses developed 
for implementing EVD vaccines11 12 and COVID-19 vacci-
nation guidelines developed by the World Health Orga-
nization (WHO).13
Literature review
We searched Embase, MEDLINE and Global Health data-
bases in early February 2021. Searches were not restricted 
by location, year of publication or language. Search 
Table 1 Characteristics of the selected vaccines
Criteria
Ebola virus disease (rVSV- 
ZEBOV) Yellow fever (17D) Meningitis A (MenAfriVac)
Cold chain requirements −70°C 2°C–8°C72 2°C–8°C73
Dose regimen Single dose Single dose Single dose74
Target populations during 
outbreak- related campaigns
Adults aged ≥18 years*
Healthcare workers, contacts of 
confirmed cases and contacts of 
contacts
Children and adults† aged ≥9 
months72
Children and adults aged 1–29 years74
Regions Democratic Republic of Congo, 
Burundi, Guinea, Liberia, Sierra 
Leone, Rwanda, Uganda
Africa and South America ‘Meningitis belt’ in Africa—sub- Saharan 
Africa from Senegal to Ethiopia73
Year developed/licensed 201975 192772 201073
Key similarities with COVID-19 
vaccines
Primarily targeted adults; 
required ultra- cold chain 
management
Targeted adults as well as 
children
Targeted adults as well as children
*Children aged 6–17 years also included in some phase 1–3 trials76; children >6 months were included in the 2018–2020 outbreak in Democratic 
Republic of Congo under compassionate use protocol.77
†Upper limit age group varied by outbreak.
Key questions
What do the new findings imply?
 ► Previous vaccination campaigns conducted during epidemics are an 
important source of transferable lessons that can assist countries in 
their COVID-19 vaccine rollouts and future epidemic preparedness.
 ► Our findings suggest that countries can strengthen vaccination 
campaigns during epidemics by recruiting local health workers to 
assist vaccination teams, by providing operational funding for pre- 
campaign community engagement and social mobilisation activi-
ties, and by examining the effectiveness of vaccination training and 
developing new models where needed.
 ► Implementing these lessons for COVID-19, however, relies on coun-
tries having sufficient vaccine supply.
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terms are provided in online supplemental appendix 
1. For inclusion, articles were required to (1) focus on 
an LMIC in Africa or South America, and (2) describe 
the implementation of one of the selected vaccines. 
Following de- duplication, we conducted title and abstract 
screening, followed by full- text screening. Texts meeting 
these criteria were cross- referenced to identify additional 
relevant papers for inclusion. Data were extracted from 




Using a purposive sampling approach, we identified 
technical experts through the professional networks of 
the research team and via ‘snowball sampling’. Partici-
pants had either (1) involvement in the rollout of one or 
more of the selected vaccines through global initiatives 
or organisations, or (2) implementation experience with 
one or more of the selected vaccines at either a regional, 
national or subnational level.
Data collection
We developed a semi- structured interview guide, based on 
preliminary findings from the literature review and using 
the thematic framework (table 2). The interview guide 
helped elicit specific information across the domains 
but was sufficiently flexible to allow the interview to be 
guided by the participants’ experiences. While the inter-
views focused on the three selected vaccines, interviewers 
did not dissuade participants from drawing on their expe-
riences from other campaigns. Participants were given 
the opportunity to reflect on their experiences with the 
initial COVID-19 vaccination rollout, where appropriate.
Interviews were conducted virtually via Zoom and were 
in either English or French. Interviews were digitally 
recorded, professionally translated to English when 
required and transcribed. The interviewers verified each 
transcript to ensure accuracy before commencing data 
analysis.
Data analysis
We analysed the qualitative data thematically, using 
deductive and inductive coding in NVivo V.12 Plus. A 
coding framework was developed based on the seven 
domains in the thematic framework (table 2), along with 
additional themes emerging from the data. Key trends, 
barriers, enablers and lessons shared by participants were 
identified across each theme.
RESULTS
Literature review
Thirty- seven studies met the inclusion criteria (figure 1): 
15 meningitis A14–28 ; 11 EVD29–39 ; 8 yellow fever40–47 ; 
one meningitis A and yellow fever48 ; and two focusing on 
general vaccination strategies.49 50 Twenty- eight studies 
focused on African countries14–38 43 47 49 50 ; two on South 
American countries44 46 ; and six studies did not specify a 
region39–42 45 48 (table 3).
Key informant interviews
Twenty- four key informants were interviewed from late 
February to late April 2021. Participants included health 
professionals and technical officers working for national 
health agencies, multilateral organisations (including 
United Nations agencies), non- governmental organisa-
tions (NGOs) and academia. All participants had worked 
with at least one of the selected vaccines in LMICs, with 
23 reflecting on their vaccination campaign experiences 
across West, Central and East Africa, and one on their 
experiences in South America. Sixty- three per cent of 
Table 2 Thematic framework for the implementation of vaccines
Domain Description
1. Planning and coordination Macro/microplanning; funding; vaccination campaign management; decision- making; coordination 
and communication mechanisms; stakeholder engagement; stakeholder roles; policy and regulatory 
framework.
2. Target groups and delivery 
strategies
Target group inclusion and exclusion criteria; prioritisation of groups; communication of target groups; 
delivery strategies for vaccination (eg, house- to- house, fixed post, mobile fixed post); tailoring of 
delivery strategies to reach subgroups.
3. Logistics and supply Supply chain; infrastructure; vaccine storage; cold chain (and ultra- cold chain) management; 
transportation; equipment (including personal protective equipment); waste disposal.
4. Vaccination teams Team composition and roles; recruitment; training techniques and processes; team coordination and 
communication.
5. Vaccination monitoring and 
safety surveillance
Identifying cases of disease and differentiating between similar pathogens; recording, reporting and 
monitoring vaccination coverage; identification, reporting and management of adverse events following 
immunisation; use of technology.
6. Community engagement 
and social mobilisation*
Developing relationships with communities and working together to conduct vaccination activities; 
strategies to increase vaccine demand and uptake, including communication strategies.
7. Vaccine confidence† Perceptions and attitudes toward the vaccine; factors contributing to confidence or resistance; types 
of rumours and misinformation; strategies to address rumours and misinformation.
*The WHO definitions of community engagement and social mobilisation were used in this research, however it was noted that these terms were 
often used interchangeably by key informants.78 79
†Vaccine confidence was not identified in articles retrieved in the literature review but was discussed in the key informant interviews.
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participants were male (15 of 24). The average interview 
length was 1 hour (range 40–80 min).
Key lessons for COVID-19 vaccination
We present findings from the literature review and qual-
itative interviews together, according to the thematic 
framework. Illustrative quotes have been included along 
with the participant’s organisation type and regions 
where they worked with the selected vaccines.
Planning and coordination
Early engagement with diverse stakeholders to support campaign 
planning
Successful vaccination campaigns engage early with a 
broad network of stakeholders to support detailed pre- 
campaign planning. Collaboration with other govern-
ment departments (eg, Ministries of Education, Finance 
and Transport) was considered crucial by interview partic-
ipants, since health teams often relied on their support 
to conduct activities. Involving staff at the health facility 
level was critical to understand context, geography and 
social nuances within their catchment area.
For the success of the campaign, we must have a strong 
microplan, originating from the health facility itself that 
is going to be involved. … [without this] you may still suc-
ceed in the vaccination coverage, but you will have a lot of 
hurdles. (National health agency, East Africa)
While participants noted the time pressures of reactive 
vaccination campaigns, the importance of engaging and 
planning with health facility staff and communities before 
commencing vaccination was consistently emphasised.
International partners, such as multilateral organisa-
tions, NGOs and civil society organisations, play a key 
role in supporting campaign resourcing and implemen-
tation. Disease- specific initiatives, such as the Meningitis 
Vaccine Project and the Eliminate Yellow Fever Epidemics 
strategy, have assisted with access to vaccines, supported 
vaccine implementation and promoted mutual learning 
between countries.16 However, participants did raise 
concerns about the sustainability of mass vaccination 
activities without such external support.26–28
COVAX and other initiatives are working to improve 
access to COVID-19 vaccines for LMICs. Still, some partic-
ipants called attention to a gap in operational funding 
needed to support vaccination activities, such as commu-
nity engagement.
As long as the funds for operations are available, then it 
will be much easier for us to roll out any vaccine activity. … 
Fine, you are giving us the vaccine free of charge, but you 
should also factor in the operational costs. (Multilateral or-
ganisation, East Africa)
Insufficient operational funding has impaired some 
countries’ capacity to conduct preparatory activities for 
COVID-19 vaccination campaigns, such as raising aware-
ness and encouraging vaccine uptake among health 
workers; participants were apprehensive about vaccine 
uptake in the absence of such activities.
Figure 1 Literature review flow chart.
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Establishing strong coordination mechanisms
Robust coordination mechanisms are necessary to 
provide direction and oversight over campaign activi-
ties. Participants highlighted the benefits of an incident 
management system (IMS) that delineates the roles 
and responsibilities of government departments (eg, 
disease control, routine immunisation, national drug 
authorities) and partner organisations and prevents the 
duplication of response efforts.
[The IMS] helped us to coordinate the partners, because 
at the beginning of Ebola in West Africa, everybody took 
the money, went into the community without asking the 
others. [It was a] nightmare, until we found this coordina-
tion mechanism, this harmonisation of all the priorities in 
Table 3 Studies identified through the literature review
Author Year
Disease Location
Meningitis A Ebola Yellow fever General Africa South America Global
Aguado et al14 2015 X       X     
Burchett et al15 2014 X       X     
Marchetti et al16 2012 X       X     
Zipursky et al17 2014 X       X     
Djingarey et al18 2012 X       X     
Cibrelus et al19 2015 X       X     
Okwo- Bele and 
Cherian20
2011 X       X     
Tartof et al21 2013 X       X     
Mbaeyi et al22 2020 X       X     
Daugla et al23 2014 X       X     
Nkwenkeu et al24 2020 X       X     
Patel et al25 2019 X       X     
Diomande et al26 2015 X       X     
Berlier et al27 2015 X       X     
Djingarey et al28 2015 X       X     
Ughasoro et al29 2015   X     X     
Wolf et al30 2020   X     X     
Jusu et al31 2018   X     X     
Samai et al32 2018   X     X     
Dean et al33 2019   X     X     
Hossmann et al34 2019   X     X     
Grantz et al35 2019   X     X     
Juan- Giner et al36 2019   X     X     
Elemuwa et al37 2015   X     X     
Alenichev et al38 2020   X     X     
Folayan et al39 2016   X         X
Tomashek et al40 2019     X       X
Chen and Hamer41 2017     X       X
Vannice et al42 2018     X       X
Barrett43 2016     X   X     
Possas et al44 2018     X     X   
Martins et al45 2013     X       X
Flamand et al46 2019     X     X   
Legesse et al47 2018     X   X     
Nguyen and 
Richardson48
2019 X   X       X
Yakum et al49 2015       X X     
Sow et al50 2018       X X     
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one single strategic response plan. (Multilateral organisa-
tion, West and Central Africa)
Within the IMS, technical working groups (eg, 
logistics, social mobilisation) can foster collaboration 
between health agencies and international partners. 
In relation to COVID-19, some participants outlined 
how they were drawing on the strength of previously 
established technical working groups to conduct 
rapid vaccination preparations. The need for effec-
tive communication both within and between working 
groups was emphasised during interviews. Regarding 
EVD vaccination campaigns, some participants high-
lighted how the ‘industry’ of the outbreak led to compe-
tition and fragmentation. Different response teams (eg, 
contact tracing and vaccination teams) vied to demon-
strate their unique contributions and retain high- paying 
positions.35
Target groups and delivery strategies
Target groups and community perceptions
Vaccinating adults requires a shift in community under-
standing of vaccination, which is traditionally associated 
with children. Perceptions and suspicions around adult 
target groups need to be recognised and accounted for 
in vaccination planning. Participants highlighted how 
communities might have concerns around both being 
included and excluded from vaccination target groups. 
For example, the inclusion of adults of reproductive age 
was frequently associated with concerns that vaccines 
affected fertility. On the other hand, some participants 
noted concerns from pregnant women about being 
initially excluded from receiving the rVSV- ZEBOV 
vaccine. Younger adults, notably young men, were 
described in both the literature and interviews as often 
being indifferent to meningitis A or yellow fever vacci-
nation; their perceived risk of contracting the disease 
or developing severe outcomes was low so they did not 
see the benefit of being vaccinated. Interview partici-
pants also outlined how older adults sometimes needed 
convincing that it was worthwhile to vaccinate them in 
their stage of life.
“No, no, no, at my age,” some will tell you, “at my age I 
think I'm just about due, [to die].” … [We use] persuasions 
in line with trying to make them valuable to society. (Na-
tional health agency and academia, East Africa)
Participants spoke of spending considerable time 
explaining the disease and the vaccine development, 
safety and regulatory processes to communities, along 
with why adults were being targeted for vaccination. 
This type of meaningful engagement with communi-
ties is critical to facilitate a better understanding of the 
disease and address community concerns around vacci-
nation target groups. However, participants noted that 
time and resources (eg, staff, development of messages, 
training, transport and per diems) are required for this 
process.
Tailoring delivery strategies
Tailored delivery strategies are required for groups 
that experience either physical or social barriers to 
accessing vaccination. For example, young adult men 
were sometimes unable to access vaccination sites due 
to work commitments during meningitis A campaigns. 
To improve uptake, vaccination centres were positioned 
near facilities they frequented, such as workplaces, hotels, 
restaurants and transport hubs.28 Social and cultural 
norms were also identified as potential barriers to vacci-
nation. During meningitis A campaigns in West Africa, 
sociocultural beliefs sometimes prevented men from 
attending vaccination centres at the same time as women 
and children.28 Similarly, one participant (Multilateral 
organisation, East and West Africa) described how young 
married women might not be able to attend a public 
vaccination site without authorisation from their spouses. 
Engaging with community leaders to map social groups 
and identify when, where and how vaccination teams can 
most effectively reach subgroups is vital to achieving high 
vaccination coverage.
Integrating vaccination campaigns with other health services
Participants highlighted how accessing remote locations 
during vaccination campaigns can be viewed as an impor-
tant opportunity to provide other health services. Inte-
grating multiple vaccination campaigns can minimise 
time burdens on both communities and health workers 
and can potentially increase uptake by offering addi-
tional health services that the community prioritises. For 
example, one participant (National health agency, West 
Africa) described how vaccination uptake in nomadic 
communities increased following the development of a 
collaborative human–animal health initiative where vacci-
nations and health assessments for community members 
and their livestock were conducted during the same visit. 
While some participants viewed multiservice integration 
positively, they also mentioned challenges around the 
coordination and reporting of multiple activities.
Integrating COVID-19 vaccination with other services 
requires careful planning with communities to prevent 
potential spillover of COVID-19 vaccine hesitancy to 
other services. In some settings, participants had already 
observed an adverse effect on the uptake of other vaccines 
due to COVID-19.
Some [community members] are really against COVID-19 
vaccination, they say “no, you want to smuggle in the 
COVID-19 vaccine in the name of yellow fever.” (National 
health agency, West Africa)
Consequently, participants outlined how vaccina-
tion teams have had to differentiate between vaccines 
for COVID-19 and vaccines for other pathogens, reas-
suring communities that the dispensed vaccine was not 
a COVID-19 vaccine. This differentiation was seen to be 
the only way to ensure that the uptake of other vaccines 
was not compromised, but it adds to the complexity of 
messaging for COVID-19 vaccines.
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Logistics and supply
Vaccine storage and transportation
Participants outlined how vaccine storage assessments 
were necessary before each campaign and stressed 
how quickly capacity could change at the facility level, 
affecting product viability. During meningitis A clinical 
trials, mock- up shipments of MenAfriVac were sent to 
each country to test the supply chain and ensure the 
vaccines had been correctly handled throughout their 
journey.16 In- depth logistical planning exercises and 
simulations can help identify and mitigate potential areas 
of vaccine wastage.15 51
Subnational vaccine storage hubs that enable the rapid 
movement of supplies during a campaign are critical to 
success, particularly in areas where it is difficult to esti-
mate the target population. Storage requirements may 
differ depending on the vaccine; some vaccines (ie, rVSV- 
ZEBOV, mRNA vaccines for COVID-19) require ultra- 
cold chain (UCC) infrastructure while others (ie, 17D, 
MenAfriVac, viral vector vaccines for COVID-19) can be 
stored at 2°C–8°C. While centralised depots with reliable 
access to electricity may seem most effective, some partic-
ipants felt that centralisation led to unacceptable delays. 
Increasing storage capacity and cold chain management 
at the subnational level was seen as a solution to ensure 
the timely distribution of vaccines during a campaign.
During EVD vaccine clinical trials, significant invest-
ments were made to ensure appropriate UCC infrastruc-
ture was in place.31 Interview participants believed that 
UCC was generally well managed during EVD outbreaks. 
However, they also emphasised that qualified staff (eg, 
pharmacists, consultants) were employed to manage 
this process during well- resourced campaigns. Multi-
dose vaccine vials simplified UCC storage and transport, 
requiring less space than single- dose vials, but one partic-
ipant (NGO, Central Africa) noted how concerns around 
vaccine wastage with multidose vials affected how vaccina-
tion teams interacted with those waiting to be vaccinated. 
In some instances, vaccination teams would wait for suffi-
cient eligible persons to arrive before opening the vial to 
limit the risk of vaccine wastage. This approach assumed 
that community members could wait, sometimes for 
hours, to receive their vaccination.
[Vaccination teams] wouldn't open a vial until [enough] 
people were there … [community members] would arrive 
at 8 am and they would still be there at 4 pm, waiting for 
the other people to turn up. And if [the vaccination team] 
didn't get [enough] people they wouldn't open the vial 
and they would go away again. (NGO, Central Africa)
Vaccination teams
Recruiting, training and resourcing vaccination teams
Participants consistently referred to the importance of 
recruiting local health workers who have established 
links to the community, can speak the local language and 
can leverage existing rapport to increase uptake, rather 
than bringing in staff from other regions.
If we need healthcare people, we try to take the village 
nurses themselves, we train them in the activity, and they 
go to meet the community. … So training the local com-
munity is very good, not finding the people in the capital 
and sending them to the village. (Multilateral organisation, 
West and Central Africa)
However, local recruitment depends on the availa-
bility of skilled workers and may place additional work-
load on already overburdened staff. Seconding staff to 
vaccination activities can also adversely affect the quality 
and availability of routine health services. Participants 
referred to how the outbreak response ‘industry’ during 
EVD outbreaks drained the local health workforce, with 
staff leaving routine posts to gain higher salaries in the 
response.
Recruiting new graduates and recently retired health 
staff to support large- scale vaccination campaigns was 
a strategy identified in both the literature and inter-
views.32 However, participants were wary of introducing 
a parallel system that potentially excludes existing, 
trusted frontline health workers from vaccination 
campaigns. Some participants also highlighted lengthy 
recruitment processes as a barrier to bringing on addi-
tional staff.
Provision of training for vaccination teams is an essen-
tial component of pre- campaign activities,15 but partic-
ipants highlighted issues around training quality at the 
lower levels of the frequently used ‘cascade’ or ‘training- 
of- trainers’ model. Training deficiencies are often picked 
up and corrected in the field through supervision, 
participants outlined, but this is resource intensive. The 
transition to remote training to comply with COVID-19 
physical distancing guidelines has introduced additional 
barriers to training delivery; many settings have limited 
access to hardware and stable internet. Participants also 
raised concerns regarding the quality of training on prac-
tical skills through virtual methods.
Most people couldn't access the internet and use a virtual 
platform. … And when you evaluate the performance [of 
the training], it is very low, because most people couldn't 
attend it. (National health agency, East Africa)
Even when in- person training has been possible, phys-
ical distancing measures have reduced the capacity of 
commonly used training facilities, thereby restricting the 
number of people able to take part.
Inadequate resourcing of vaccination teams and 
lengthy processes for distributing funding were iden-
tified as additional barriers, with participants stating 
that it was unfair to expect teams to perform without 
funding.
[The resources] must be available, and that is very key, 
available and handed to the people that actually get in-
volved, because if you are going to keep the team in the 
field for the whole day and they don't have support or any 
money to get themselves a drink or something to eat, it is 
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Vaccination monitoring and safety surveillance
Locally led, integrated vaccination monitoring
The ability to link a person to their vaccination, any 
subsequent adverse events following immunisation, and 
any breakthrough infections is an important aspect of 
vaccination campaign monitoring and can increase 
community confidence by providing organised, accurate 
information on the progress of the campaign. However, 
outside of clinical trials, most interview participants 
described complex data aggregation processes where 
indicators held in different datasets were collated and 
compared. Innovations in electronic case- based surveil-
lance systems, such as the use of quick response (QR) 
codes and new modules to track immunisation status and 
adverse events following immunisation, were mentioned 
by a small number of participants in relation to COVID-
19. Nevertheless, most of these systems still involved a 
combination of entering data on paper in the field and 
subsequently inputting the data to electronic systems 
at higher levels (ie, district level). Parallel systems and 
limited standardisation in data collection can severely 
hamper the analysis and operational use of vaccination 
coverage, vaccine efficacy and vaccine safety data.30
Participants highlighted how limited access to data held 
by different organisations negatively affected response 
efforts. In one example, a participant (NGO, Central 
Africa) reported that government health staff could not 
compare newly confirmed EVD cases against the records 
of those who had been vaccinated due to a lack of access 
to crucial datasets held by other organisations. Partici-
pants described tensions when governments were not 
sufficiently supported in the ownership, storage, access 
and analysis of vaccination data, highlighting the impor-
tance of these elements for the success of campaigns.
Community engagement and social mobilisation
Timing and approach of community engagement
Community engagement and social mobilisation are vital 
components of a successful vaccination campaign. Partic-
ipants repeatedly raised the importance of having a clear 
strategy for engaging with communities, with consistent 
messaging around the disease, the vaccine, vaccination 
target groups and adverse events following immunisa-
tion. Some participants linked the success of meningitis 
A vaccination to the Meningitis Vaccine Project’s detailed 
communication plan, which was developed, implemented 
and refined over a few years. Importantly, participants 
outlined, the objective of the Meningitis Vaccine Project’s 
communication plan was to build community awareness 
and expectation for the vaccine well in advance of the 
campaigns.
The population was very aware [of meningitis], they were 
really waiting for this vaccine. When we did the [menin-
gitis A] vaccination campaign … the vaccination centres 
opened at 8 am, but at 5 am people were already queuing 
to get the vaccine. (Multilateral organisation, West, Central 
and East Africa)
While participants recognised that reactive vaccina-
tion campaigns face intense time pressures, they insisted 
that community engagement should precede vaccination 
campaigns by a minimum of 1–2 months. This lead- in 
time is necessary to develop relationships with commu-
nity members, respond to vaccination queries and tailor 
delivery strategies.
Participants stressed that early vaccine acceptance 
could not be taken as indicative of community senti-
ment throughout a campaign. Continuous engagement 
with communities was considered crucial to monitoring 
community acceptance, responding to concerns around 
vaccine safety and explaining the rationale behind target 
group selection. Reconnecting with communities and 
providing feedback at the end of the campaign were 
also deemed essential in enhancing trust and building 
sustainable relationships that would support future 
vaccine uptake.
The feedback to the community leaders is very, very im-
portant, because we always seek their permission, their 
help, their assistance, but we never give them feedback. 
(Multilateral organisation, West Africa)
Respect, honesty and meaningful discussion were 
stressed as principles crucial to building trust:
There are many things that the communities need to un-
derstand. They may not be intellectual … but they are not 
stupid. They observe and ask relevant questions. So one 
of the keys is to never hide the truth. Be frank and honest 
with them, because when they trust you, they trust you for-
ever. But when you lose [their] confidence, it’s difficult. 
(Multilateral organisation, West and Central Africa)
Communities want to actively participate in discus-
sions about the need for, or benefit of, new vaccines.47 
Providing community members with an opportunity 
to ask questions and query points about the disease or 
vaccine is a crucial enabler for vaccination success. Partic-
ipants outlined how engaged community members often 
became champions for the campaign.
Participants affirmed that vaccines for well- known and 
feared diseases, like meningitis A and yellow fever, gener-
ally had high community uptake, but social mobilisation 
was much more difficult if diseases were not known or 
prioritised by communities. Generating demand for 
vaccination where communities had other priorities 
outside the health sector was particularly challenging.
[Community members] would say “What we need is a 
bridge, we need a road to be repaired. … When you have 
those things, bring the [vaccination] request.” (National 
health agency, West Africa)
Addressing this challenge, participants said, required 
detailed and focused communication about the disease 
beyond simple vaccine uptake advocacy; working with 
communities to ensure they had appropriate information 
to understand the disease, its severity and the burden on 
their communities.47 Data on disease incidence are crit-
ical to these discussions. Some participants highlighted 
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concerns that limited COVID-19 case detection in African 
countries would negatively impact community percep-
tions of disease burden and the need for vaccination.
The current limited supply of COVID-19 vaccines 
presents a paradox for LMICs in terms of community 
engagement and social mobilisation. While delayed 
vaccine delivery means countries have more time to plan 
mobilisation activities, they lack the operational funding 
required to design and deliver these activities. Further, 
generating demand in the face of limited supply requires 
careful balancing of risks; some participants spoke of 
how they had not yet employed previously used demand 
generation methods, such as short message service 
(SMS) alerts, for COVID-19 for fear of overwhelming 
their limited vaccine supply.
Vaccine confidence
Responding to vaccine concerns
Swift, transparent and trusted responses are needed to 
address vaccine concerns. Participants stated that the 
longer a rumour circulates, the greater the risk to a 
vaccination campaign. Influencers—political, religious, 
and traditional leaders or heads of social groups (eg, 
women’s groups, youth groups or sporting groups)—play 
an important role in counteracting negative rumours. 
When rumours were spread by a prominent individual, 
such as a religious leader, participants described using a 
similarly influential person to counter those messages. 
Rumours spread by health professionals were especially 
difficult to address and were best responded to by other 
health professionals. National Immunisation Technical 
Advisory Groups can also play a role in fostering commu-
nity confidence and dispelling rumours by providing 
independent, evidence- based information on the disease 
and the vaccination campaign.
Vaccine hesitancy in the COVID-19 response was 
perceived as particularly challenging compared with 
previous campaigns. Participants attributed this to the 
global nature of the pandemic and the propagation of 
rumours through social media.
The problem is that COVID-19 is too publicised, which is 
already a major obstacle to acceptance. … Unfortunately 
today, the world cannot control [the information] because 
everyone has become an expert in COVID-19 vaccination 
or an expert in COVID-19. (Multilateral organisation, West 
and Central Africa)
Several participants described how social media 
tracking and online rumour debunking were incorpo-
rated into their COVID-19 response activities. Some coun-
tries have partnered with social media and technology 
companies to provide accurate information through their 
messaging forums. However, other participants described 
this as a weaker area of their response, highlighting that 
further investment was needed to counter the prolifera-
tion of misinformation and rumours. While participants 
described the unique challenge of rumours circulating 
on social media, they also stressed the importance of 
continued face- to- face interaction with communities to 
understand and respond to rumours in person rather 
than relying on information distributed online.
Participants noted that rumours around ‘vaccine 
testing’ were prevalent in both the EVD and COVID-19 
responses, but that community risk perceptions were 
different between the campaigns.
[During the EVD response] there was lots of talk about be-
ing guinea pigs and [people] would say, “yeah, we’re guin-
ea pigs”, but a lot of people went, “actually, I'd rather be 
a guinea pig and get vaccinated than get Ebola.” … Early 
on in the COVID-19 outbreak [the population] said, “well, 
we're not willing to be guinea pigs for this one because it’s 
not our problem … we are probably not going to die of 
COVID-19.” (NGO, Central Africa)
Participants spoke of how they explained the vaccine 
regulatory and approval processes to communities, high-
lighting that COVID-19 vaccine trials had already been 
conducted in other countries outside of Africa. However, 
changing community perceptions was considered difficult 
due to misinformation and the absence of high disease 
incidence or severity that might increase the prioritisa-
tion of COVID-19 vaccination within communities.
DISCUSSION
This research took place as the first doses of COVID-19 
vaccines provided through COVAX arrived in LMICs in 
Africa and South America. We reviewed the literature 
and interviewed technical experts with extensive expe-
rience in epidemic vaccination campaigns to develop 
recommendations for the rollout of COVID-19 vaccines 
in LMICs. Table 4 presents a set of recommendations.
To date, gaps in operational funding for COVID-19 
vaccination campaigns in LMICs have prevented some 
vaccination teams from conducting crucial commu-
nity engagement activities. Mobilising communities in 
the face of limited COVID-19 vaccine supply is a diffi-
cult balance. Nevertheless, while waiting for sufficient 
vaccines to be delivered, countries can involve commu-
nities in the proposed rollout, listen to their concerns 
and devise solutions. It is crucial that countries prioritise 
operational funds to support vaccination teams to effec-
tively conduct these preparatory activities.
There are several advantages to employing local 
health workers in vaccination campaigns. Building on 
existing trust and rapport, local health workers can 
engage with communities, discuss key information about 
the campaign, monitor vaccine acceptance levels and 
respond to rumours as they arise. In order to employ local 
health workers who are not yet supporting the COVID-19 
response, countries must identify mechanisms to rapidly 
recruit and train them. Evidence around effective training 
strategies for health workers in LMICs during epidemics 
remains limited.52 53 While the ‘cascade’ or ‘training- 
of- trainers’ model is seen as economical and rapidly 
scalable,54 participants highlighted issues of quality as 
information is transmitted to lower levels. Considering 
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the key role health workers play in mobilising communi-
ties and delivering vaccinations, countries must evaluate 
and refine training strategies to effectively upskill their 
vaccination teams for COVID-19.
Co- administration of COVID-19 with other vaccines is 
not currently recommended by the WHO Strategic Advi-
sory Group of Experts on Immunization,55 preventing 
potential efficiency gains through integration. While 
integration can reduce time and cost burdens, it intro-
duces challenges around coordination, reporting and 
staff capacity.56 Further, COVID-19 vaccine hesitancy may 
affect the uptake of other vaccines. The differentiation 
between COVID-19 and other vaccines has perpetuated 
the belief that some vaccines are safe while others are 
not. Without a concerted effort to change community 
perceptions around COVID-19 vaccines, integrating 
other campaigns with COVID-19 vaccination is unlikely 
to yield high uptake. Integrating other community- 
prioritised health services (eg, antenatal care) may be 
a more effective strategy. Careful planning with other 
health programmes and communities is needed to iden-
tify and mitigate the potential effect of COVID-19 vaccine 
hesitancy on other services. Considering the significant 
impact of COVID-19 on access to routine health services 
in LMICs,57 58 the integration of services should be 
discussed and pursued where appropriate.
Most COVID-19 vaccines currently under Emer-
gency Use Listing by the WHO are packaged in multi-
dose vials.59–64 Multidose vaccine vials are widely used 
in LMICs as they are cheaper and require less storage 
space.65 However, health workers’ reluctance to open 
multidose vials for fear of vaccine wastage was identified 
in this research and has also been reported for routine 
immunisation programmes in LMICs.24 66 The limited 
supply of COVID-19 vaccines is likely to increase pressure 
on vaccination teams to minimise wastage, which may be 
complicated by the strict prioritisation of target groups 
and instances where sufficient eligible persons do not 
present for vaccination. To minimise wastage and reduce 
the risk of loss to follow- up, vaccination teams should be 
given clear guidelines for administering the remaining 
doses in multidose vials to persons outside of priority 
groups.
Incident Management Systems provide direction and 
coordination across response activities, including vacci-
nation. However, the unprecedented scale and extended 
duration of the COVID-19 pandemic have placed 
enormous pressure on key personnel within response 
Table 4 Recommendations for the implementation of COVID-19 vaccines in LMICs, based on lessons from meningitis A, 
yellow fever and Ebola virus disease vaccination campaigns
Recommendation Domains
Prioritise the availability of operational funds to support community 
engagement and social mobilisation well in advance of vaccination activities.
 ► Planning and coordination
 ► Community engagement and social mobilisation
Develop a community engagement strategy that emphasises the principles of 
community involvement, co- development and iterative adaptation. Vaccination 
teams should meet iteratively with community members, actively seek 
their questions and input on strategy development, and adapt vaccination 
strategies accordingly.
 ► Community engagement and social mobilisation
 ► Target groups and delivery strategies
 ► Vaccine confidence
Engage local, trusted health workers (including community health workers) 
to support vaccination activities, ensuring a continued connection between 
communities and the vaccination campaign.
 ► Vaccination teams
 ► Community engagement and social mobilisation
Develop rapid processes to recruit and manage an expanded vaccination 
workforce for the response. Care should be taken to balance response staffing 
requirements with the need to maintain existing services.
 ► Vaccination teams
Evaluate and refine training strategies to ensure vaccination teams are well 
equipped to conduct vaccination activities. Identify teams who are not able to 
access remote training and design suitable alternatives.
 ► Vaccination teams
Provide vaccination teams with clear guidance on the management of 
multidose vaccine vials, including which population groups should be offered 
leftover vaccine doses where the vial cannot be appropriately stored and used 
at a later time.
 ► Vaccination teams
 ► Logistics and supply
Ensure national ownership, access and capacity to analyse vaccination 
campaign data, including the use of electronic data capture systems.
 ► Vaccination monitoring and safety surveillance
Work with technical leads across the outbreak response (eg, surveillance, 
vaccination) to streamline the collection, aggregation and analysis of different 
indicators to support vaccination campaign monitoring.
 ► Vaccination monitoring and safety surveillance
Bring together response pillar leads and routine health programme leads 
to discuss opportunities to integrate health services during vaccination 
campaigns. Any integration of services should be well resourced and well 
coordinated between services and with communities, to mitigate potential 
adverse impacts.
 ► Target groups and delivery strategies
LMICs, low- and middle- income countries.
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structures. The IMS model is labour intensive.67 68 While 
there has been a global recognition of frontline worker 
burnout, the effect of a protracted pandemic on key 
personnel in countries’ IMS should also be considered.69 
Countries need to explore ways to streamline coordina-
tion processes and upskill additional staff to fulfil IMS 
functions to ensure continuity in the response.
Previous research into the barriers to vaccination has 
uncovered some similar findings, including the impor-
tance of defining target groups, building trust at the 
community level and ensuring that training is fit for 
purpose.6 51 70 Most of these studies focused on routine, 
primarily childhood, vaccinations, but many of the 
lessons are equally relevant to the three vaccines in our 
research and COVID-19 vaccines.
There are several limitations to this study that might 
limit the generalisability of the findings. First, unlike 
most COVID-19 vaccines, the three selected vaccines were 
delivered using a single- dose regimen. Multidose vaccines 
add complexity to vaccine delivery but have been used 
in previous vaccination campaigns targeting children, 
from which lessons can be drawn.71 Second, due to the 
geographical distribution of the selected diseases and the 
distribution of the research team’s professional networks, 
this research draws primarily from vaccine implemen-
tation experiences in LMICs in West, Central and East 
Africa. The findings may not be generalisable to other 
geographical areas, which are likely to have their own set 
of challenges in implementing vaccines. Finally, several 
identified technical experts could not participate due to 
competing priorities, including the COVID-19 response 
and the EVD outbreaks in the first half of 2021.
CONCLUSION
Key recommendations generated from this research 
include prioritising time, funding and workforce for 
community engagement; identifying effective training 
strategies to upskill vaccination teams; streamlining 
response coordination and vaccination monitoring func-
tions and exploring opportunities for health service 
integration. These recommendations rely on LMICs 
having sufficient vaccine supply to conduct vaccination 
campaigns for COVID-19, which has not been the case 
in most settings. We implore the global community 
to prioritise COVID-19 vaccine supply for LMICs. As 
vaccine supplies increase, we encourage researchers to 
support countries in monitoring and documenting their 
COVID-19 vaccination campaigns to understand real- 
time responses to challenges and strengthen evidence 
around best practices during outbreak- related vaccina-
tion campaigns in low- resource settings.
Author affiliations
1UK Public Health Rapid Support Team, London School of Hygiene & Tropical 
Medicine/Public Health England, London, UK
2Department of Infectious Disease Epidemiology, Faculty of Epidemiology and 
Population Health, London School of Hygiene & Tropical Medicine, London, UK
3Gates Ventures, Kirkland, Washington, USA
Acknowledgements The authors would like to thank the technical experts who 
took time out of their busy schedules in the midst of the COVID-19 pandemic 
and concurrent outbreaks to give interviews and who generously shared their 
experiences, knowledge and insights to support this research.
Contributors All authors provided input into the conceptualisation of the study 
and its design. The interviews and qualitative analysis were conducted by JC and 
RW with support from DK. The literature review was conducted by DK with support 
from KAN and JC. The manuscript was prepared by JC and DK. All authors provided 
input into the manuscript and are guarantors of the study.
Funding This research was funded by UK Aid from the Department of Health and 
Social Care (https:// www. gov. uk/ government/ collections/ officialdevelopment- 
assistance- oda–2, Grant No. IS- RRT-1015-001) via the UK Public Health Rapid 
Support Team Research Programme. The UK Public Health Rapid Support Team is 
funded by UK Aid from the Department of Health and Social Care and is jointly run 
by Public Health England and the London School of Hygiene & Tropical Medicine.
Disclaimer The views expressed in this publication are those of the author(s) and 
not necessarily those of the Department of Health and Social Care.
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval The study was approved by the London School of Hygiene & 
Tropical Medicine Research Ethics Committee (ref: 24044).
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement All data relevant to the study are included in the 
article or uploaded as supplemental information.
Supplemental material This content has been supplied by the author(s). It has 
not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been 
peer- reviewed. Any opinions or recommendations discussed are solely those 
of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and 
responsibility arising from any reliance placed on the content. Where the content 
includes any translated material, BMJ does not warrant the accuracy and reliability 
of the translations (including but not limited to local regulations, clinical guidelines, 
terminology, drug names and drug dosages), and is not responsible for any error 
and/or omissions arising from translation and adaptation or otherwise.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the 
use is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iDs
Julie Collins http:// orcid. org/ 0000- 0002- 0673- 3649
Kate A Nelson http:// orcid. org/ 0000- 0001- 7747- 1482
Hana Rohan http:// orcid. org/ 0000- 0002- 5327- 6348
Hilary Bower http:// orcid. org/ 0000- 0002- 1541- 6637
David S Kennedy http:// orcid. org/ 0000- 0003- 0004- 6167
REFERENCES
 1 Skegg D, Gluckman P, Boulton G, et al. Future scenarios for the 
COVID-19 pandemic. Lancet 2021;397:777–8.
 2 The Lancet Microbe. COVID-19 vaccines: the pandemic will not end 
overnight. Lancet Microbe 2021;2:e1–e.
 3 So AD, Woo J. Reserving coronavirus disease 2019 vaccines for 
global access: cross sectional analysis. BMJ 2020;371:m4750.
 4 Mathieu E, Ritchie H, Ortiz- Ospina E, et al. A global database of 
COVID-19 vaccinations. Nat Hum Behav 2021;5:947–53.
 5 World Health Organization. COVAX Announces additional deals 
to access promising COVID-19 vaccine candidates; plans global 
rollout starting Q1 2021, 2020. Available: https://www. who. int/ news/ 
item/ 18- 12- 2020- covax- announces- additional- deals- to- access- 
promising- covid- 19- vaccine- candidates- plans- global- rollout- 
starting- q1- 2021 [Accessed 25 Jan 2021].
 6 Guignard A, Praet N, Jusot V, et al. Introducing new vaccines in low- 
and middle- income countries: challenges and approaches. Expert 
Rev Vaccines 2019;18:119–31.
 7 Acharya KP, Ghimire TR, Subramanya SH. Access to and equitable 













ealth: first published as 10.1136/bm






12 Collins J, et al. BMJ Global Health 2021;6:e006951. doi:10.1136/bmjgh-2021-006951
BMJ Global Health
 8 Bangura JB, Xiao S, Qiu D, et al. Barriers to childhood immunization 
in sub- Saharan Africa: a systematic review. BMC Public Health 
2020;20:1108.
 9 Oku A, Oyo- Ita A, Glenton C, et al. Factors affecting the 
implementation of childhood vaccination communication strategies 
in Nigeria: a qualitative study. BMC Public Health 2017;17:200.
 10 Oyo- Ita A, Wiysonge CS, Oringanje C, et al. Interventions for 
improving coverage of childhood immunisation in low- and middle- 
income countries. Cochrane Database Syst Rev 2016;7:CD008145.
 11 World Health Organization. Global Ebola Vaccine Implementation 
Team (GEVIT) Practical guidance on the use of Ebola vaccine in an 
outbreak response, 2016.
 12 Ebola Vaccine Deployment, Acceptance and Compliance (EBODAC) 
Consortium. Ebola vaccine communication, community engagement 
and compliance management (3C) gap analysis tool, 2019.
 13 World Health Organization, UNICEF. Guidance on developing a 
national deployment and vaccination plan for COVID-19 vaccines: 
interim guidance, 2020.
 14 Aguado MT, Jodar L, Granoff D, et al. From epidemic meningitis 
vaccines for Africa to the meningitis vaccine project. Clin Infect Dis 
2015;61 Suppl 5:S391–5.
 15 Burchett HED, Mounier- Jack S, Torres- Rueda S, et al. The impact of 
introducing new vaccines on the health system: case studies from 
six low- and middle- income countries. Vaccine 2014;32:6505–12.
 16 Marchetti E, Mazarin- Diop V, Chaumont J, et al. Conducting 
vaccine clinical trials in sub- Saharan Africa: operational challenges 
and lessons learned from the meningitis vaccine project. Vaccine 
2012;30:6859–63.
 17 Zipursky S, Djingarey MH, Lodjo J- C, et al. Benefits of using 
vaccines out of the cold chain: delivering meningitis a vaccine 
in a controlled temperature chain during the mass immunization 
campaign in Benin. Vaccine 2014;32:1431–5.
 18 Djingarey MH, Barry R, Bonkoungou M, et al. Effectively introducing 
a new meningococcal a conjugate vaccine in Africa: the Burkina 
Faso experience. Vaccine 2012;30 Suppl 2:B40–5.
 19 Cibrelus L, Lingani C, Fernandez K, et al. Risk assessment and 
meningococcal a conjugate vaccine introduction in Africa: the 
district prioritization tool. Clin Infect Dis 2015;61 Suppl 5:S442–50.
 20 Okwo- Bele J- M, Cherian T. The expanded programme on 
immunization: a lasting legacy of smallpox eradication. Vaccine 
2011;29 Suppl 4:D74–9.
 21 Tartof S, Cohn A, Tarbangdo F, et al. Identifying optimal vaccination 
strategies for serogroup a Neisseria meningitidis conjugate vaccine 
in the African meningitis belt. PLoS One 2013;8:e63605.
 22 Mbaeyi S, Sampo E, Dinanibè K, et al. Meningococcal carriage 7 
years after introduction of a serogroup a meningococcal conjugate 
vaccine in Burkina Faso: results from four cross- sectional carriage 
surveys. Lancet Infect Dis 2020;20:1418–25.
 23 Daugla DM, Gami JP, Gamougam K, et al. Effect of a serogroup 
A meningococcal conjugate vaccine (PsA- TT) on serogroup A 
meningococcal meningitis and carriage in Chad: a community study 
[corrected]. Lancet 2014;383:40–7.
 24 Nkwenkeu SF, Jalloh MF, Walldorf JA, et al. Health workers' 
perceptions and challenges in implementing meningococcal 
serogroup a conjugate vaccine in the routine childhood 
immunization schedule in Burkina Faso. BMC Public Health 
2020;20:254.
 25 Patel JC, Soeters HM, Diallo AO, et al. MenAfriNet: a network 
supporting case- based meningitis surveillance and vaccine 
evaluation in the meningitis belt of Africa. J Infect Dis 
2019;220:S148–54.
 26 Diomandé FVK, Djingarey MH, Daugla DM, et al. Public health 
impact after the introduction of PsA- TT: the first 4 years. Clin Infect 
Dis 2015;61 Suppl 5:S467–72.
 27 Berlier M, Barry R, Shadid J, et al. Communication challenges during 
the development and introduction of a new meningococcal vaccine 
in Africa. Clin Infect Dis 2015;61 Suppl 5:S451–8.
 28 Djingarey MH, Diomandé FVK, Barry R, et al. Introduction and 
Rollout of a new group A meningococcal conjugate vaccine (PsA- 
TT) in African meningitis belt countries, 2010-2014. Clin Infect Dis 
2015;61 Suppl 5:S434–41.
 29 Ughasoro MD, Esangbedo DO, Tagbo BN, et al. Acceptability and 
willingness- to- pay for a hypothetical Ebola virus vaccine in Nigeria. 
PLoS Negl Trop Dis 2015;9:e0003838.
 30 Wolf J, Bruno S, Eichberg M, et al. Applying lessons from the Ebola 
vaccine experience for SARS- CoV-2 and other epidemic pathogens. 
NPJ Vaccines 2020;5:51.
 31 Jusu MO, Glauser G, Seward JF, et al. Rapid establishment of 
a cold chain capacity of -60°C or Colder for the strive Ebola 
vaccine trial during the Ebola outbreak in Sierra Leone. J Infect Dis 
2018;217:S48–55.
 32 Samai M, Seward JF, Goldstein ST, et al. The Sierra Leone trial to 
introduce a vaccine against Ebola: an evaluation of rVSV∆G- ZEBOV- 
GP vaccine tolerability and safety during the West Africa Ebola 
outbreak. J Infect Dis 2018;217:S6–15.
 33 Dean NE, Gsell P- S, Brookmeyer R, et al. Design of vaccine 
efficacy trials during public health emergencies. Sci Transl Med 
2019;11:eaat0360.
 34 Hossmann S, Haynes AG, Spoerri A, et al. Data management of 
clinical trials during an outbreak of Ebola virus disease. Vaccine 
2019;37:7183–9.
 35 Grantz KH, Claudot P, Kambala M, et al. Factors influencing 
participation in an Ebola vaccine trial among front- line workers in 
guinea. Vaccine 2019;37:7165–70.
 36 Juan- Giner A, Tchaton M, Jemmy J- P, et al. Safety of the rVSV 
ZEBOV vaccine against Ebola Zaire among frontline workers in 
guinea. Vaccine 2019;37:7171–7.
 37 Elemuwa C, Kutalek R, Ali M, et al. Global lessons from Nigeria's 
ebolavirus control strategy. Expert Rev Vaccines 2015;14:1397–400.
 38 Alenichev A, Peeters Grietens K, Gerrets R. Conceptions within 
misconceptions: Pluralisms in an Ebola vaccine trial in West Africa. 
Glob Public Health 2020;15:13–21.
 39 Folayan MO, Yakubu A, Haire B, et al. Ebola vaccine development 
plan: ethics, concerns and proposed measures. BMC Med Ethics 
2016;17:10.
 40 Tomashek KM, Challberg M, Nayak SU, et al. Disease resurgence, 
production capability issues and safety concerns in the context of 
an aging population: is there a need for a new yellow fever vaccine? 
Vaccines 2019;7:179.
 41 Chen LH, Hamer DH. Vaccination challenges in confronting the 
resurgent threat from yellow fever. JAMA 2017;318:1651–2.
 42 Vannice K, Wilder- Smith A, Hombach J. Fractional- Dose yellow fever 
vaccination — advancing the evidence base. N Engl J Med Overseas 
Ed 2018;379:603–5.
 43 Barrett ADT. Yellow fever in Angola and beyond — the problem 
of vaccine supply and demand. N Engl J Med Overseas Ed 
2016;375:301–3.
 44 Possas C, Lourenço- de- Oliveira R, Tauil PL, et al. Yellow fever 
outbreak in Brazil: the puzzle of rapid viral spread and challenges for 
immunisation. Mem Inst Oswaldo Cruz 2018;113:e180278.
 45 Martins RM, Maia MdeLS, Farias RHG, et al. 17DD yellow fever 
vaccine. Hum Vaccin Immunother 2013;9:879–88.
 46 Flamand C, Bailly S, Fritzell C, et al. Vaccination coverage in the 
context of the emerging yellow fever threat in French Guiana. PLoS 
Negl Trop Dis 2019;13:e0007661.
 47 Legesse M, Endale A, Erku W, et al. Community knowledge, 
attitudes and practices on yellow fever in South Omo area, southern 
Ethiopia. PLoS Negl Trop Dis 2018;12:e0006409.
 48 Nguyen T, Richardson S. Vaccine stockpile governance through 
partnership: the International coordination group on emergency 
vaccine provision and its impacts. Int J Infect Dis 2019;79:132–3.
 49 Yakum MN, Ateudjieu J, Walter EA, et al. Vaccine storage and cold 
chain monitoring in the North West region of Cameroon: a cross 
sectional study. BMC Res Notes 2015;8:145.
 50 Sow C, Sanou C, Medah C, et al. Challenges of cold chain quality 
for routine EPI in south- west Burkina- Faso: an assessment 
using automated temperature recording devices. Vaccine 
2018;36:3747–55.
 51 Kochhar S, Rath B, Seeber LD, et al. Introducing new vaccines in 
developing countries. Expert Rev Vaccines 2013;12:1465–78.
 52 Nayahangan LJ, Konge L, Russell L, et al. Training and education of 
healthcare workers during viral epidemics: a systematic review. BMJ 
Open 2021;11:e044111.
 53 Rowe AK, Rowe SY, Peters DH, et al. The effectiveness of training 
strategies to improve healthcare provider practices in low- income 
and middle- income countries. BMJ Glob Health 2021;6:e003229.
 54 Mormina M, Pinder S. A conceptual framework for training of trainers 
(TOT) interventions in global health. Global Health 2018;14:100.
 55 World Health Organization. Interim recommendations for use of the 
Pfizer–BioNTech COVID-19 vaccine, BNT162b2 under emergency 
use listing 2021.
 56 Mounier- Jack S, Mayhew SH, Mays N. Integrated care: learning 
between high- income, and low- and middle- income country health 
systems. Health Policy Plan 2017;32:iv6–12.
 57 Roberton T, Carter ED, Chou VB, et al. Early estimates of the indirect 
effects of the COVID-19 pandemic on maternal and child mortality in 
low- income and middle- income countries: a modelling study. Lancet 
Glob Health 2020;8:e901–8.
 58 Dixit SM, Sarr M, Gueye DM, et al. Addressing disruptions in 
childhood routine immunisation services during the COVID-19 













ealth: first published as 10.1136/bm






Collins J, et al. BMJ Global Health 2021;6:e006951. doi:10.1136/bmjgh-2021-006951 13
BMJ Global Health
 59 World Health Organization. AstraZeneca ChAdOx1- S/nCoV-19 
[recombinant], COVID-19 vaccine, 2021.
 60 World Health Organization. Janssen Ad26.COV2- S [recombinant], 
COVID-19 vaccine, 2021.
 61 World Health Organization. Moderna mRNA-1273, COVID-19 
vaccine, 2020.
 62 World Health Organization. Pfizer/BioNTech COMIRNATY®, 
COVID-19 vaccine, 2021.
 63 World Health Organization. Sinopharm [Vero Cell]- Inactivated, 
COVID-19 vaccine, 2021.
 64 World Health Organization. Background document on the inactivated 
vaccine Sinovac- CoronaVac against COVID-19, 2021.
 65 Drain PK, Nelson CM, Lloyd JS. Single- dose versus multi- dose 
vaccine vials for immunization programmes in developing countries. 
Bull World Health Organ 2003;81:726–31.
 66 Krudwig K, Knittel B, Karim A, et al. The effects of switching from 10 
to 5- dose vials of MR vaccine on vaccination coverage and wastage: 
a mixed- method study in Zambia. Vaccine 2020;38:5905–13.
 67 Richard B, Robert H, Paul C. Adapting the Incident Management 
System for response to health emergencies - early experience of 
WHO. Weekly epidemiological record 2018;93:279–83.
 68 Olu OO, Lamunu M, Chimbaru A, et al. Incident management 
systems are essential for effective coordination of large disease 
outbreaks: perspectives from the coordination of the Ebola outbreak 
response in Sierra Leone. Front Public Health 2016;4:254.
 69 Deng D, Naslund JA. Psychological impact of COVID-19 pandemic 
on frontline health workers in low- and middle- income countries. 
Harv Public Health Rev 2020;28.
 70 Guzman- Holst A, DeAntonio R, Prado- Cohrs D, et al. Barriers to 
vaccination in Latin America: a systematic literature review. Vaccine 
2020;38:470–81.
 71 LaMontagne DS, Barge S, Le NT, et al. Human papillomavirus 
vaccine delivery strategies that achieved high coverage in 
low- and middle- income countries. Bull World Health Organ 
2011;89:821–30.
 72 World Health Organization. Vaccines and vaccination against yellow 
fever. WHO position paper, 2013.
 73 World Health Organization. Meningococcal vaccines: WHO position 
paper, 2011.
 74 World Health Organization . WHO position paper, meningococcal 
a conjugate vaccine: updated guidance, February 2015. Vaccine 
2018;36:57–68.
 75 World Health Organization. WHO prequalifies Ebola vaccine, paving 
the way for its use in high- risk countries, 2019. Available: https://
www. who. int/ news/ item/ 12- 11- 2019- who- prequalifies- ebola- 
vaccine- paving- the- way- for- its- use- in- high- risk- countries [Accessed 
19 Apr 2021].
 76 Bache BE, Grobusch MP, Agnandji ST. Safety, immunogenicity 
and risk- benefit analysis of rVSV-∆G- ZEBOV- GP (V920) Ebola 
vaccine in phase I- III clinical trials across regions. Future Microbiol 
2020;15:85–106.
 77 World Health Organization. Ebola virus disease: vaccines, 2020. 
Available: https://www. who. int/ news- room/ q- a- detail/ ebola- vaccines 
[Accessed 11 Jul 2021].
 78 World Health Organization. Community engagement: a health 
promotion guide for universal health coverage in the hands of the 
people, 2020.
 79 World Health Organization. Communication for behavioural impact: 













ealth: first published as 10.1136/bm








APPENDIX 1: Literature review search terms 
MEDLINE 
1. meningococcal vaccines/ or ebola vaccines/ or yellow fever vaccine/  
2. ("ebola" or "yellow fever" or "meningitis a" or "meningococcal a" or "meningococcal 
meningitis").ab,ti,kw.  
3. meningitis, meningococcal/ or hemorrhagic fever, ebola/ or yellow fever/  
4. 2 or 3  
5. ("immuni?ation" or "vaccin*" or "ervebo" or "17d" or "MenAfriVac").ab,ti,kw.  
6. 1 or 5  
7. 4 and 6  
8. Vaccines/ad, lj, st, sd [Administration & Dosage, Legislation & Jurisprudence, 
Standards, Supply & Distribution]  
9. Immunization Programs/lj, mt, og, st, sd [Legislation & Jurisprudence, Methods, 
Organization & Administration, Standards, Supply & Distribution]  
10. implementation science/  
11. "Delivery of Health Care"/  
12. 8 or 9 or 10 or 11  
13. 7 and 12  
GLOBAL HEALTH 
1. ("immuni?ation" or "vaccin*" or "ervebo" or "17d" or "MenAfriVac").ab,ti,sh.  
2. ("ebola" or "yellow fever" or "meningitis a" or "meningococcal a" or "meningococcal 
meningitis").ab,ti,sh.  
3. (("immunisation" or "vaccin*") adj3 ("uptake" or "strateg*" or "feasibility" or 
"program*" or "campaign" or "delivery" or "roll?out")).ab,ti,sh.  
4. 1 and 2 and 3  
EMBASE 
1. meningococcal vaccines/ or ebola vaccines/ or yellow fever vaccine/  
2. ("ebola" or "yellow fever" or "meningitis a" or "meningococcal a" or "meningococcal 
meningitis").ab,ti,kw.  
3. meningitis, meningococcal/ or hemorrhagic fever, ebola/ or yellow fever/  
4. 2 or 3  
5. ("immuni?ation" or "vaccin*" or "ervebo" or "17d" or "MenAfriVac").ab,ti,kw.  
6. 1 or 5  
7. 4 and 6  
8. vaccination coverage/ or vaccination refusal/  
9. implementation science/  
10. (("immunisation" or "vaccin*") adj2 ("uptake" or "strateg*" or "feasibility" or 
"program*" or "campaign" or "delivery" or "roll?out")).ab,ti,kw.  
11. 8 or 9 or 10  




BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Global Health
 doi: 10.1136/bmjgh-2021-006951:e006951. 6 2021;BMJ Global Health, et al. Collins J
